Filtrer vos résultats
- 9
- 3
- 5
- 4
- 1
- 1
- 1
- 9
- 3
- 1
- 1
- 2
- 1
- 2
- 4
- 1
- 1
- 12
- 11
- 3
- 2
- 1
- 12
- 8
- 4
- 2
- 2
- 2
- 1
12 résultats
|
|
|
triés par
|
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021.2017
Pré-publication, Document de travail
hal-02152419v1
|
|||
Empirical economic analysis of orphan drug legislation impact on innovationEur. Health Economic Association Conf., Jul 2016, Hamburg, Germany
Communication dans un congrès
hal-02195798v1
|
|||
|
|
Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech CompaniesBerndt, E.R.; Goldman, D.P.; Rowe, J. Economic Dimensions of Personalized and Precision Medicine, University of Chicago Press Books, pp.305-334, 2019, 9780226611068. ⟨10.7208/chicago/9780226611235.003.0011⟩
Chapitre d'ouvrage
hal-02152424v1
|
||
Empirical Economic Analysis of Orphan Drug InnovationNBER Conference : Economic Dimensions of Personalized and Precision Medecine, Sep 2016, New York, United States
Communication dans un congrès
hal-02273799v1
|
|||
Are patents signals for the IPO market? An EU–US comparison for the software industryResearch Policy, 2014, 43 (8), pp.1299-1311
Article dans une revue
hal-01135634v1
|
|||
Empirical Economic Analysis of Orphan Drug InnovationNBER Economic Dimensions of Personalized and Precision Medicine, Sep 2017, Santa Monica. CA,, United States
Communication dans un congrès
hal-02195838v1
|
|||
|
|
Where do we go? VC firm heterogeneity and the exit routes of newly listed high-tech firmsSmall Business Economics, 2021, 57, pp.1339-1359. ⟨10.1007/s11187-020-00351-x⟩
Article dans une revue
hal-02797121v1
|
||
|
|
Highly-skilled migrants and Cross-border M&A: Firm-level evidenceJournal of International Business Studies, 2020, 51, pp.737-763. ⟨10.1057/s41267-018-0203-3⟩
Article dans une revue
halshs-02024499v1
|
||
Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech CompaniesDRUID Society Conf., Jun 2016, Copenhague, Denmark
Communication dans un congrès
hal-02195744v1
|
|||
Orphan Drug Designations as Valuable intangible assets for Ipo Investors in Pharma-biotech companies65th Annual Meeting of the French Economic Association,, Jun 2015, Nancy, France
Poster de conférence
hal-02195963v1
|
|||
|
|
Highly skilled and well connected: Migrant inventors in cross-border M&AsJournal of International Business Studies, 2020, 51 (5), pp.737-763. ⟨10.1057/s41267-018-0203-3⟩
Article dans une revue
hal-03097926v1
|
||
Empirical Economic Analysis of Orphan Drug InnovationNBER Economic Dimensions of Personalized and Precision Medicine, Columbia Univ., Sep 2016, New York, United States
Communication dans un congrès
hal-02195829v1
|